Nippon Shinyaku Co., Ltd. (TYO:4516)
Japan
· Delayed Price · Currency is JPY | Market Cap | 338.55B |
| Revenue (ttm) | 160.55B |
| Net Income (ttm) | 31.95B |
| Shares Out | 67.40M |
| EPS (ttm) | 474.07 |
| PE Ratio | 10.60 |
| Forward PE | 13.29 |
| Dividend | 124.00 (2.87%) |
| Ex-Dividend Date | Mar 30, 2026 |
| Volume | 259,700 |
| Average Volume | 350,050 |
| Open | 5,023.00 |
| Previous Close | 4,323.00 |
| Day's Range | 5,023.00 - 5,023.00 |
| 52-Week Range | 2,967.00 - 5,023.00 |
| Beta | -0.48 |
| RSI | 88.53 |
| Earnings Date | Nov 14, 2025 |
About Nippon Shinyaku
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan and internationally. The company operates through Pharmaceuticals and Functional Food Business segments. It offers drugs in the fields of urology, hematology, intractable and rare diseases, gynecology, and other diseases; health food ingredients, preservatives, protein preparations, and supplements. The company in the Strategic Partnership with Nippon Shinyaku to develop ATSN-10 that is in Phase I/II of clinical trials for the treatment of GUCY2D-mutant Leb... [Read more]
Financial Performance
In 2024, Nippon Shinyaku's revenue was 160.23 billion, an increase of 8.08% compared to the previous year's 148.26 billion. Earnings were 32.56 billion, an increase of 25.94%.
Financial StatementsNews
Nippon Shinyaku H1 Net Profit Declines
(RTTNews) - Nippon Shinyaku reported that its first half profit attributable to owners of parent was 15.76 billion yen, down 3.7% from last year. Earnings per share was 233.88 yen compared to 243.07 y...
Regenxbio Secures A Partnership With Nippon Shinyaku For RGX-111 & 121
REGENXBIO partners with Nippon Shinyaku for MPS therapies
Why KB Home Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
Shares of KB Home (NYSE: KBH) rose sharply in today's pre-market trading after the company posted better-than-expected fourth-quarter financial results. KB Home reported fourth-quarter revenue of $2 ...
Week In Review: Nippon Shinyaku Signs $735m Deal For DMD Therapy
Japan’s Nippon Shinyaku will acquire European rights for a Duchenne muscular dystrophy disease therapy developed by Capricor Therapeutics of San Diego. Read more here.
Capricor Therapeutics partners with Nippon Shinyaku for European commercialization of Deramiocel
Capricor Therapeutics partners with Nippon Shinyaku for European distribution of Duchenne muscular dystrophy treatment, deramiocel.
EXCLUSIVE: Capricor Therapeutics Inks European Expansion, Commercialization Pact For Lead Asset With Japanese Pharma Firm
Tuesday, Capricor Therapeutics Inc (NASDAQ: CAPR) entered into a binding term sheet with Nippon Shinyaku Co., Ltd. , a Japanese pharmaceutical company, for the commercialization and distribution in E...